BCL10: A Potential Drug Target for Immune and Cellular Processes

Target Name: BCL10

NCBI ID: G8915

BCL10

BCL10: A Potential Drug Target for Immune and Cellular Processes

BCL10 (BCL10 immune signaling adaptor, transcript variant 1) is a protein that plays a crucial role in the immune system. It is a member of the BCL1 family, which includes proteins that are involved in the regulation of cell death, apoptosis, and inflammation. BCL10 is expressed in a wide range of tissues and cells, including immune cells, and it is involved in the regulation of immune responses, cell proliferation, and survival.

In recent years, researchers have become increasingly interested in BCL10 as a potential drug target. BCL10 has been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, BCL10 has been shown to be involved in the regulation of cellular processes that are important for the development of cancer, such as cell proliferation, angiogenesis, and metastasis.

One of the reasons why BCL10 has generated so much interest as a drug target is its location in the genome. BCL10 is located on chromosome 18, which makes it a potential target for drugs that can interact with its gene or its protein product. Additionally, BCL10 is a transmembrane protein, which means that it spans the cell membrane and can interact with both intracellular and extracellular molecules. This makes it a potentially more accessible target for drugs that can inhibit its function.

Another reason why BCL10 has generated interest as a drug target is its role in the regulation of immune responses. BCL10 is involved in the regulation of T cell development and function, as well as the regulation of antibody production. Additionally, BCL10 is involved in the regulation of inflammation, which is a critical part of the immune response.

In addition to its role in the immune system, BCL10 is also involved in the regulation of cell death and apoptosis. This is important because disruptions in cell death and apoptosis can contribute to the development and progression of a variety of diseases, including cancer. Additionally, BCL10 is involved in the regulation of cell cycle progression, which is important for the development of cancer because changes in the cell cycle can contribute to the development of cancer.

Despite the potential benefits of BCL10 as a drug target, there are also potential drawbacks to its use. One of the main concerns is the potential adverse effects of BCL10 inhibitors. BCL10 is involved in the regulation of many important cellular processes, so inhibiting its function can have a wide range of effects on the body. Additionally, BCL10 is involved in the regulation of cell death and apoptosis, which can make it a potential target for drugs that are effective in these processes.

In conclusion, BCL10 is a protein that plays a crucial role in the immune system and has been shown to be involved in the regulation of many important cellular processes. As a result, BCL10 has generated a lot of interest as a potential drug target. While there are potential benefits to BCL10 inhibitors, there are also potential drawbacks to their use. Further research is needed to fully understand the role of BCL10 as a drug target and to develop safe and effective treatments.

Protein Name: BCL10 Immune Signaling Adaptor

Functions: Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation (PubMed:10187770, PubMed:10364242, PubMed:10400625, PubMed:25365219, PubMed:24074955). Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:24074955). Recruited by activated CARD domain-containing proteins: homooligomerized CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex (PubMed:24074955). This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:18287044, PubMed:27777308, PubMed:24074955). Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity (PubMed:26488816). Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR) (PubMed:18264101, PubMed:18287044, PubMed:27777308, PubMed:24074955). Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK (PubMed:10187815)

The "BCL10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCL10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets